# US 8,771,688 B2 · Method of treating malignant mesothelioma > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,771,688 B2 - Document ID: US8771688B2 - Status: Granted - Kind: B2 - Application number: 13/385,206 - Filed: 2012-02-07 - Published: 2014-01-02 - Granted: 2014-07-08 - Earliest claimed: 2007-03-14 - Assignees: The University of Tokyo - Applicants: Chikao Morimoto; Kei Ohnuma; Teruo Inamoto - Inventors: Chikao Morimoto; Kei Ohnuma; Teruo Inamoto - Web page: https://patentgrep.com/patent/US8771688B2 ## CPC - A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines} - A61K 31/7088: Compounds having three or more nucleosides or nucleotides - A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) - A61P 35/00: Antineoplastic agents - C07K 16/40: against enzymes - C12N 15/1138: {against receptors or cell surface proteins} - A61K 2039/505: {comprising antibodies} - C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered - C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC] - C12N 2310/14: interfering nucleic acids [NA] - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present invention relates to a therapeutic agent for malignant mesothelioma comprising a substance which inhibits binding of CD26 to extracellular matrix such as an siRNA targeting CD26 cDNA or an anti-CD26 antibody. The present invention also relates to a method of treating malignant mesothelioma, which comprises administering the substance to a patient in need thereof. ## Claims ### Claim 1 A method for the treatment of malignant mesothelioma, comprising a step of administering an effective amount of an anti-CD26 humanized antibody comprising a variable region of 14D10 to a subject in need thereof. ### Claim 2 (depends on 1) The method according to claim 1, wherein the humanized antibody is produced by a strain designated s604069YST-pABMC148 (x411) with American Type Culture Collection accession number PTA-7695. ### Claim 3 (depends on 1) The method according to claim 1, wherein an effective amount of an effector cell specific to the antibody is administered to the subject together with the antibody. ### Claim 4 (depends on 1) The method according to claim 1, wherein the antibody is administered in an amount ranging from 1 μg/kg to 100 mg/kg of body weight of the subject per day. ### Claim 5 (depends on 1) The method according to claim 1, wherein the antibody is administered in an amount of at least 1 μg/kg of body weight of the subject per day. ### Claim 6 A method for inhibiting growth of a malignant mesothelioma cell, which comprises contacting a malignant mesothelioma cell with an anti-CD26 humanized antibody comprising a variable region of 14D10. ### Claim 7 (depends on 6) The method according to claim 6, wherein the humanized antibody is produced by a strain designated s604069YST-pABMC148 (x411) with American Type Culture Collection accession number PTA-7695. ### Claim 8 A method for inhibiting growth of a malignant mesothelioma cell, which comprises contacting the malignant mesothelioma cell and an effector cell with an anti-CD26 humanized antibody comprising a variable region of 14D10, wherein the effector cell is a cell specific to the antibody. ### Claim 9 (depends on 8) The method according to claim 8, wherein the humanized antibody is produced by a strain designated s604069YST-pABMC148 (x411) with American Type Culture Collection accession number PTA-7695. ### Claim 10 A method for lysing a malignant mesothelioma cell, which comprises contacting the malignant mesothelioma cell and an effector cell with an anti-CD26 humanized antibody comprising a variable region of 14D10, wherein lysis of the cell is caused by antibody-dependent cell-mediated cytotoxicity and wherein the effector cell is a cell specific to the antibody. ### Claim 11 (depends on 10) The method according to claim 10, wherein the humanized antibody is produced by a strain designated s604069YST-pABMC148 (x411) with American Type Culture Collection accession number PTA-7695. ### Claim 12 A method for lysing a malignant mesothelioma cell, which comprises contacting the malignant mesothelioma cell and an effector cell with an anti-CD26 humanized antibody comprising a variable region of 14D10, wherein the effector cell is a cell specific to the antibody.